Fludarabine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Fludarabine: Toward Plasma Cell Myeloma (Original Indication Not on Record)
One-Sentence Summary
Fludarabine is a purine nucleoside antimetabolite chemotherapy agent; the evidence pack for this candidate does not contain a documented original approved indication or market license. The TxGNN model predicts it may be effective for Plasma Cell Myeloma, with 50 clinical trials and 20 publications currently associated with this direction — though most of this body of evidence reflects fludarabine’s well-established role as a stem-cell transplant conditioning agent rather than direct evidence of anti-myeloma monotherapy efficacy.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no approved-indication or license text on file) |
| Predicted New Indication | Plasma Cell Myeloma |
| TxGNN Prediction Score | 99.82% |
| Evidence Level | L2 |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for fludarabine is not available in this evidence pack, and no original approved indication is on record for cross-reference. However, other entries within this same dataset independently describe fludarabine’s pharmacology: it is a purine nucleoside analog that inhibits DNA synthesis and induces apoptosis in malignant marrow cells and lymphocytes. This mechanism underlies its long-standing, well-documented use as a core component of induction regimens (e.g., FLAG-IDA) and as the backbone of reduced-intensity/nonmyeloablative conditioning regimens ahead of allogeneic stem-cell and CAR-T therapies for hematologic malignancies.
For plasma cell myeloma specifically, the rationale is twofold. First, there is direct preclinical evidence (PMID 17976186) that fludarabine inhibits human myeloma cell lines both in vitro and in vivo, concomitant with decreased Akt phosphorylation. Second, fludarabine is widely used — alone or combined with melphalan/bortezomib — as the conditioning backbone for allogeneic transplantation and, increasingly, as the lymphodepletion regimen preceding BCMA-directed CAR-T and bispecific-antibody therapies in myeloma.
That said, this evidence base has an important limitation: no completed Phase 3 randomized controlled trial specifically tests fludarabine as a stand-alone anti-myeloma treatment (as opposed to a supportive/conditioning agent). The large majority of trials and publications capture fludarabine’s role within a transplant or cellular-therapy regimen, not as an independently validated therapeutic option for myeloma. This distinction should be kept in mind when interpreting the TxGNN prediction score.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01231412 | Phase 3 | Completed | 174 | Randomized comparison of post-transplant immunosuppression strategies to prevent acute GVHD after fludarabine-based nonmyeloablative conditioning in hematologic malignancies (including myeloma); fludarabine is a background conditioning agent, not the trial’s primary endpoint drug. |
| NCT00427557 | Phase 2 | Completed | 31 | Tested adding umbilical cord blood to standard stem-cell transplant conditioning (including fludarabine) for advanced hematologic malignancies, including myeloma, to improve transplant response and evaluate safety. |
| NCT04098393 | Phase 1 | Active, not recruiting | 39 | Pilot study of a condensed busulfan/melphalan/fludarabine conditioning regimen plus ATG before CD34+-selected allogeneic transplant for various blood cancers, including myeloma. |
| NCT06577025 | Phase 2 | Active, not recruiting | 43 | Evaluates different treatment sequences of cilta-cel, talquetamab, and teclistamab after DVRd induction in newly diagnosed standard-risk multiple myeloma; fludarabine is used for pre-CAR-T/bispecific lymphodepletion. |
| NCT06242249 | Phase 1/2 | Not yet recruiting | 10 | Determines safety and maximum tolerated dose of anti-BCMA CAR-NK cell therapy in relapsed/refractory multiple myeloma, with fludarabine included in the lymphodepleting pre-treatment. |
| NCT00560053 | Phase 3 | Completed | 500 | Multicenter “Multiple Myeloma 2000” trial evaluating an optimized therapeutic strategy including tandem autotransplantation (BUMEL) for multiple myeloma, with analysis of minimal residual disease and prognostic impact. |
| NCT00615589 | Phase 2 | Terminated | 22 | Allogeneic HSCT with reduced-toxicity myeloablative conditioning for high-risk multiple myeloma patients who typically relapse after autologous transplant, testing whether a graft-versus-myeloma effect improves outcomes. |
| NCT03767725 | Phase 1 | Unknown | 10 | Anti-BCMA and/or anti-CD19 CAR T-cell therapy for relapsed multiple myeloma refractory to chemotherapy and prior autologous transplant, using fludarabine-based lymphodepletion before CAR-T infusion. |
| NCT03322735 | Phase 1/2 | Unknown | 10 | BCMA-targeted CAR-T cells (with fludarabine/cyclophosphamide lymphodepletion) for safety and feasibility assessment in relapsed/refractory multiple myeloma. |
| NCT04579523 | Phase 1 | Not yet recruiting | 30 | Dose-escalation trial of ²¹¹At-labeled anti-CD38 monoclonal antibody combined with fludarabine (± cyclophosphamide and low-dose TBI) as pre-transplant conditioning for high-risk multiple myeloma. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38483213 | 2024 | Phase 1 trial | American Journal of Clinical Oncology | Phase 1 study of bortezomib + fludarabine + melphalan (± total marrow irradiation) as allogeneic HSCT conditioning for high-risk/relapsed-refractory multiple myeloma. |
| 17310135 | 2007 | Retrospective cohort | Bone Marrow Transplantation | Multicenter analysis of fludarabine + treosulfan reduced-toxicity conditioning before allogeneic SCT in 34 myeloma patients; regimen found feasible. |
| 15389436 | 2004 | Cohort | Biology of Blood and Marrow Transplantation | Prognostic-factor analysis of melphalan/fludarabine dose-reduced allografts in 120 myeloma patients; relapse after prior autograft and chronic GVHD were the strongest predictors of treatment-related mortality. |
| 37833271 | 2023 | Cohort | Blood Cancer Journal | Compared bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T therapy in multiple myeloma. |
| 40972962 | 2025 | Real-world cohort | Transplantation and Cellular Therapy | Fludarabine lymphodepletion exposure is associated with toxicities after idecabtagene vicleucel (ide-cel) CAR-T in relapsed/refractory multiple myeloma; highlights pharmacokinetic variability of fludarabine. |
| 36690811 | 2023 | Phase 1 trial | Nature Medicine | UNIVERSAL trial: allogeneic BCMA-targeting CAR-T (ALLO-715) with anti-CD52-containing lymphodepletion in 43 relapsed/refractory myeloma patients; established safety and tolerability. |
| 38659046 | 2024 | Long-term follow-up | Journal of Hematology & Oncology | 5-year follow-up of LEGEND-2 (first-in-human LCAR-B38M/cilta-cel BCMA CAR-T trial), showing deep and durable responses in relapsed/refractory myeloma. |
| 39365257 | 2025 | Real-world cohort | Blood | Standard-of-care outcomes of ciltacabtagene autoleucel in 236 relapsed/refractory myeloma patients across 16 US academic centers. |
| 7781758 | 1995 | Case report/commentary | European Journal of Haematology | Early report specifically discussing fludarabine use in the context of plasma cell leukemia. |
| 28473042 | 2017 | Review | Mayo Clinic Proceedings | Review of monoclonal gammopathy-associated peripheral neuropathy across the plasma cell disorder spectrum, including multiple myeloma. |
US Market Information
Currently no marketing authorization records are available for fludarabine in this evidence pack — taiwan_regulatory.total_licenses is 0 and the market status is recorded as Not Marketed.
Cytotoxicity
Fludarabine is a purine nucleoside analog / antimetabolite chemotherapy agent used across leukemia, lymphoma, and hematopoietic transplant conditioning regimens, and therefore qualifies as an antineoplastic drug for this section.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (purine nucleoside analog / antimetabolite) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information. Note that a Blocking-severity data gap (TFDA/FDA label warnings and contraindications) has been flagged for this drug and must be resolved before any safety-stage (S1) assessment can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The TxGNN system itself stages this candidate as “Research Question” (decision stage S2, evidence level L2) — supportive but not yet decision-grade evidence, since no completed Phase 3 RCT has tested fludarabine as a stand-alone anti-myeloma therapy; nearly all cited trials and publications document its role as a conditioning/lymphodepletion agent rather than a direct treatment.
- A Blocking data gap on labeled warnings and contraindications (DG001) means safety cannot yet be evaluated, and the drug is not currently marketed (0 licenses on file), further limiting near-term actionability.
To proceed, the following is needed:
- TFDA/FDA package-insert warnings, precautions, and contraindications (resolves DG001, currently Blocking)
- Documented mechanism of action and original approved indication for this candidate (resolves DG002)
- Trial-level evidence isolating fludarabine’s direct anti-myeloma activity from its conditioning/lymphodepletion role, ideally a prospective comparative study
- Drug interaction (DDI) data, currently unavailable (
query_status: not_found)
Note: Within this same evidence pack, other predicted indications carry notably stronger evidence than the top-ranked plasma cell myeloma candidate — most importantly myelodysplastic syndrome (rank 7, evidence level L1, decision stage S3, “Proceed with Guardrails”), where fludarabine is an established component of both induction chemotherapy (FLAG-IDA) and standard conditioning regimens. That candidate may warrant a separate, dedicated evaluation report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.